| Pediatric rheumatologists | Pediatric nephrologists | p-value |
---|---|---|---|
n = 56 (100%) | n = 31 (100%) | ||
Adverse effects after CYC treatment | Â | Â | Â |
 Cytopenia | 49 (88%) | 26 (84%) | 0.638 |
 Nausea | 27 (48%) | 18 (58%) | 0.378 |
 Liver toxicity | 11 (20%) | 6 (19%) | 0.974 |
 Hair loss | 12 (21%) | 15 (48%) | 0.009 |
 Hemorrhagic cystitis | 17 (30%) | 15 (48%) | 0.094 |
 Allergic reaction | 8 (14%) | 6 (19%) | 0.537 |
 Dyspnea | 4 (7%) | N/A |  |
 Infertility | 2 (4%) | N/A |  |
 Mild infection | 25 (45%) | 12 (39%) | 0.591 |
 Severe infection | 5 (9%) | 3 (10%) | 0.907 |
 No adverse effects | 1 (2%) | N/A |  |
How long after CYC did the infection develop? | Â | Â | Â |
 1 week | 20 (36%) | 8 (26%) | 0.343 |
 2 weeks | 17 (30%) | 8 (26%) | 0.653 |
 1 month | 6 (11%) | 4 (13%) | 0.759 |
 3 months | N/A | 2 (6%) |  |
Infections after CYC | Â | Â | Â |
 Upper respiratory tract infection | 31 (55%) | 14 (45%) | 0.362 |
 Lower respiratory tract infection | 10 (18%) | 12 (39%) | 0.032 |
 Herpes simplex infection | 7 (13%) | 3 (10%) | 0.835 |
 Skin infection | 3 (5%) | N/A |  |
 Urinary tract infection | 4 (7%) | 2 (6%) | 0.903 |
 CMV infection | 5 (9%) | N/A |  |
 Pneumocystis jirovecii infection | 2 (4%) | 2 (6%) | 0.539 |
 COVID-19 infection | N/A | 2 (6%) |  |
 Opportunistic fungal infection | 3 (5%) | 3 (10%) | 0.446 |
 Influenza | 3 (5%) | 1 (3%) | 0.649 |